Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure

Chimeric antigen receptor (CAR) T cell therapies have resulted in profound clinical responses in the treatment of CD19-positive hematological malignancies, but a significant proportion of patients do not respond or relapse eventually. As an alternative to CAR T cells, T cells can be engineered to ex...

Full description

Bibliographic Details
Main Authors: Tassilo L. A. Wachsmann, Anne K. Wouters, Dennis F. G. Remst, Renate S. Hagedoorn, Miranda H. Meeuwsen, Eline van Diest, Jeanette Leusen, Jürgen Kuball, J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
t cell receptor
chimeric antigen receptor
car
tcr
comparison
solid tumors
antigen exposure
exhaustion
activation-induced cell death
tumor load
Online Access:http://dx.doi.org/10.1080/2162402X.2022.2033528

Internet

http://dx.doi.org/10.1080/2162402X.2022.2033528

Similar Items